SCHEMBL362582

SCHEMBL362582

O=C(O)c1cccn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
KDM4E B2RXH2 2/20 0.57
RIPK3 Q9Y572 4/20 0.47
MET P08581 6/20 0.46
AXL P30530 2/20 0.46
RIPK2 O43353 1/20 0.46
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
NOTUM Q6P988 1/20 0.43
RXFP1 Q9HBX9 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137068 0.86 KDM4E (0.54) LMNAKDM4EMAPTALDH1A1HPGD
SCHEMBL15948862 0.85 MET (0.50) LMNAKDM4ERIPK3METAXL
SCHEMBL1161158 0.85 TYK2 (0.50) LMNAKDM4ERIPK3METAXL
SCHEMBL2477308 0.85 LMNA (0.46) LMNAKDM4ERIPK3METAXL
SCHEMBL10517562 0.85 ESR1 (0.46) LMNAKDM4EMAPTALDH1A1GAA
Hydrochloric Acid SCHEMBL23071632 0.84 TYK2 (0.49) LMNAKDM4ERIPK3METAXL
SCHEMBL26601277 0.84 KDM4E (0.47) LMNAKDM4ERIPK3METAXL
SCHEMBL26601369 0.83 AKR1C3 (0.49) LMNAKDM4ERIPK3MAPTALDH1A1
SCHEMBL4433936 0.83 CDC25B (0.50) LMNAKDM4EMAPTALDH1A1NOTUM
SCHEMBL26601309 0.83 NR4A1 (0.49) LMNAKDM4EMAPTALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9617257-B2 Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2017-04-11 US claimed
EP-2593462-B1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO LTD (CN) 2016-09-07 EP claimed
US-9242991-B2 Substituted fused heterocycles as c-Met tyrosine kinase inhibitors BETTA PHARMACEUTICALS CO., LTD (CN) 2016-01-26 US claimed
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS BETTA PHARMACEUTICALS CO., LTD. (CN) 2015-11-05 US claimed
EP-2367821-B1 C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2015-09-16 EP claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2867223-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS Betta Pharmaceuticals Co., Ltd. (CN) 2015-05-06 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
CN-102464667-B Five-membered heterocycle pyrimidine compounds, preparation method and application thereof SHANGHAI INST MATERIA MEDICA 2014-06-04 CN claimed
WO-2014000713-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS ZHEJIANG BETA PHARMA INCORPORATION (CN) 2014-01-03 WO claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
EP-2593462-A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS Zhejiang Beta Pharma Inc. (CN) 2013-05-22 EP claimed
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors BETTA PHARMACEUTICALS CO., LTD. (CN) 2013-05-16 US claimed
CN-103052641-A Novel fused heterocyclic derivatives as c-Met inhibitors ZHEJIANG BETA PHARMA INC 2013-04-17 CN claimed
CN-102464667-A Five-membered heterocyclic pyrimidine compounds, preparation method and application thereof SHANGHAI INST MATERIA MEDICA 2012-05-23 CN claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
WO-2012006960-A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS ZHEJIANG BETA PHARMA INC. (CN) 2012-01-19 WO claimed
US-20110312951-A1 C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof MERCK PATENT GMBH (DE) 2011-12-22 US claimed
EP-0308020-A2 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof MERCK & CO. INC. (US) 1989-03-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315210-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS MET, ABL1, ROS1 LMNA 4607/4885KDM4E 900/4885RIPK3 1031/4885
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB LMNA 3630/4885KDM4E 1009/4885RIPK3 399/4885
US-20110312951-A1 C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof PRKCB, PNCK, PACSIN2 LMNA 867/4885KDM4E 2223/4885RIPK3 340/4885
US-20130123286-A1 Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors MET, RET, ABL1 LMNA 4459/4885KDM4E 1318/4885RIPK3 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.